New study aims to predict late CMV infections in transplant patients
NCT ID NCT06814301
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study watches 123 stem cell transplant patients to see if their immune system's recovery after stopping a common anti-CMV drug (letermovir) predicts later CMV infection. Researchers will track immune markers and virus levels up to 200 days after transplant. The goal is to personalize how long patients need preventive treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS CELL MEDIATED IMMUNITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitario Reina Sofía
Córdoba, Córdoba, 14004, Spain
Conditions
Explore the condition pages connected to this study.